Abstract:Background Antiphospholipid syndrome (APS) is an autoimmune disease characterised mainly by arterial and/or venous thrombosis, recurrent pregnancy morbidity, with the presence of a variety of heterogeneous circulating antiphospholipid antibodies. However, there are a group of APS patients with persistently negative antiphospholipid antibodies. It is necessary to validate new specific antibodies to better recognition of these APS patients. Objectives To explore the clinical significance of non-criteria anti-phospholipid antibodies in a large cohort of Chinese patients with anti-phospholipid syndrome (APS). Methods Serum samples were obtained from 214 APS patients, 122 disease control including systemic lupus erythematosus, sjogren syndrome, ankylosing spondylitis, rheumatoid arthritis, osteoarthritis and 50 healthy control. Antiphosphatidylserine(IgA/IgG/IgM) (aPS), anti-phosphatidylethanolamine (IgA/IgG/IgM) (aPE), anti-prothrombin-antibodies (IgA/IgG/IgM) (aPT) , anti-annexin V-antibodies (IgA/IgG/IgM) (aAnxV), anti-phosoholipid-antibody(IgG/IgM)(aPL), anti-oxLDL antibody(IgG/IgM)(aoxLDL) were tested by ELISA kits(HUMAN Diagnostics Products, Germany) and IgG/IgM APhL were tested by ELISA(Louisville APL Diagnostic, USA). The Chi-square (χ2) test was used to examine the difference of frequencies of antibodies in APS patients and patients with other diseases. Spearman correlation analysis was performed to investigate the relationship between aPS/PT and other clinical/laboratory parameters. Results The prevalence of aPS IgG, aPS IgM, aPT, aPE, aAnxV, aPL, aoxLDL and IgG APhL, IgM APhL were 44.8%, 22.4%, 46.3%, 9.8%, 17.8%, 44.4%, 22.4%, 45.3% and 22.9%. The specificity of the antibodies were 82.6%, 95.3%, 96.0%, 99.4%, 95.3%, 92.4%, 87.2%, 95.3% and 94.8%. The highest positive predictive values of these antibodies were aPE. aPE, aPS IgM and APhL IgM were associated with thrombotic events and oxLDL, aPE, aPL, aPS IgG, aPS IgM, aPT, aoxLDL, APhL IgG and APHL IgM were correlated with anti-cardiolipin antibody(ACL). aPL, aPS IgG, aPS IgM, aPT, APhL IgG and APhL IgM were associated with β2-GP1 antibody. APhL IgG, APhL IgM and PS IgG were the highest prevalence in both ACL and lupus anticoagulant (LAC) negative patients. aPT has the highest prevalence in ACL and β2-GP1 negative patients and APhL IgG and aPS IgG were the highest two antibodies in LAC and β2-GP1 negative patients and aPT has the highest prevalence in seronegative APS patients. Conclusions Non-criteria aPLs have a good diagnostic value in APS and were associated with thrombotic events. References [1] Hughes GR, Khamashta MA (2003) Seronegative antiphospholipid syndrome. Ann Rheum Dis62:1127 [2] Examining the prevalence of non-criteria anti-phospholipid antibodies in patients with anti-phospholipid syndrome: a systematic review.Rheumatology2015;54:2042–2050. [3] A unique antiphospholipid assay recognizing phospholipid mixture compared with criteria antiphospholipid immunoassays in lupus patients. Lupus2017;26(6):606–615. Acknowledgements We thank all patients and healthy donors whom took part in this study. Disclosure of Interest None declared

IgG Antibodies to Plasminogen and Their Relationship to IgG Anti-Β 2 -Glycoprotein 1 Antibodies and Thrombosis

The Expression of Anti-TFPI Antibody in Antiphospholipid Syndrome and Its Clinical Signiifcance

IgG Autoantibodies to Tissue Type Plasminogen Activator and Their Relationship to Thrombosis

Autoantibodies to plasminogen and tissue plasminogen activator in women with recurrent pregnancy loss.

Anti-phosphatidylserine/prothrombin complex antibodies (aps/pt) increase the risk for thrombosisbased on lupus anticoagulantpositivity

Anti-phosphatidylserine/prothrombin Complex Antibodies (aps/pt) Increase the Risk for Thrombosis Based on Lupus Anticoagulant Positivity

Clinical Significance of Different Antiphospholipid Antibody Isotypes in Systemic Lupus Erythematosus

Anti-phosphatidylserine/prothrombin antibodies and thrombosis associate positively with HLA-DRB113 and negatively with HLA-DRB103 in SLE

Anti-{beta}2GPI-domain I antibody is associated with extra-criteria manifestations in a large prospective antiphospholipid syndrome cohort in China

Anti-β_2-glycoprotein Ⅰ antibodies in patients with systemic lupus erythematosus

Anti-β2GPI-domain I Antibody is Associated with Extra-Criteria Manifestations in a Large Prospective Antiphospholipid Syndrome Cohort in China.

Antibodies to phosphatidylserine/prothrombin (aPS/PT) enhanced the diagnostic performance in Chinese patients with antiphospholipid syndrome.

[Antiphospholipid antibodies: clinical significance and biological diagnosis]

Evaluation of the Diagnostic Potential of Antibodies to Beta2-Glycoprotein 1 Domain 1 in Chinese Patients with Antiphospholipid Syndrome

AB0559 the Prevalence of Non-Criteria Anti-Phospholipid Antibodies in Anti-Phospholipid Syndrome

Characteristics of purified Anti-β2GPI IgG N-glycosylation associate with thrombotic, obstetric, and catastrophic antiphospholipid syndrome.

Opposite Profiles of Complement in Antiphospholipid Syndrome (APS) and Systemic Lupus Erythematosus (SLE) Among Patients With Antiphospholipid Antibodies (aPL)

The (non‐)sense of detecting anti‐cardiolipin and anti‐β2glycoprotein I IgM antibodies in the antiphospholipid syndrome

Relationship between IgG Anti- 2-glycoprotein 1 Antibodies and IgG Anti-tissue type Plasminogen Activator Antibodies in Autoimmune Disease

Diagnostic Value of Antibodies to Phosphatidylserine/prothrombin Complex for Antiphospholipid Syndrome in Chinese Patients

Reevaluation of Predictive Value of ACL and Anti-Β2gp1 Antibody for Thrombosis in Patients with Systemic Lupus Erythematosus: from a Perspective of a Practical World.